Shares of Innocoll Holdings (INNL -63.2%) are in freefall after yesterday's slam by the FDA on Xaracoll. Healthcare analysts are doing a quick reset off the development.
FBR Capital: The investment firm downgrades INNL to Market Perform from Outperform and slashes its price target to $2 from $10.
Janney: The analyst team calls out the high funding risks as it lowers INNL to Market Perform from Outperform. The PT is also cut 80% to $2.
JMP: Analyst Jason Butler warns that a capital raise is likely. Shares are rated at Market Perform.
Previously: Innocoll gets refusal to file letter from FDA on XARACOLL; -52% after hours (Dec. 29)
Sources: Marketbeat.com and Bloomberg
Now read: ImmunoGen races higher »
Subscribe for full text news in your inbox